What is Alnylam Pharmaceuticals's SG&A?

Alnylam Pharmaceuticals (ALNY) reported SG&A of $347.92M in Q2 2026.

How has Alnylam Pharmaceuticals's SG&A changed year-over-year?

Alnylam Pharmaceuticals's SG&A increased by 7.6% year-over-year, from $323.31M to $347.92M.

What is the long-term trend for Alnylam Pharmaceuticals's SG&A?

Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's SG&A has grown at a 18.2% compound annual growth rate (CAGR), from $620.64M to $1.21B.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Alnylam Pharmaceuticals ALNY SG&A

SG&A at other companies

Ionis PharmaceuticalsIONS

$150.4M+66.0%

PTC TherapeuticsPTCT

$86.18M+6.5%

BridgeBio PharmaBBIO

$163.9M+54.1%

ANI PharmaceuticalsANIP

$73.66M-3.8%

Mirum Pharmaceuticals, Inc.MIRM

$96.33M+66.9%

Arrowhead ResearchARWR

——

Segments

By segment

See full

Single Reportable Segment$347.92M+7.6%

Other financials

Income statement

See full

Revenue$1.3B+66.9%

Gross profit$992.7M+57.2%

Operating income$231.4M+1,529%

Net income$164.5M+348%

EPS (diluted)$1.21+337%

Balance sheet

See full

Cash & equivalents$1.7B+53.2%

Total debt$256.4M-5.2%

Total equity$1.4B+440%

Total assets$5.6B+21.7%

Cash flow

See full

Operating cash flow$326.7M+113%

CapEx$34.7M+143%

Free cash flow$292.0M+109%

Valuation

See full

Market cap$38.51B-10.7%

Enterprise value$37.05B-12.3%

P/E52.5×—

P/S8×-9.5×

Profitability

See full

Gross margin79.8%-4.1pp

Operating margin20.8%+16.5pp

Net margin15.3%+10.7pp

FCF margin16.5%+14.8pp

Returns & leverage

See full

Return on equity91.4%—

Debt / equity0.2×-0.9×

Current ratio3.1×+0.3×

Where this comes from

Reported directly by Alnylam Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alnylam Pharmaceuticals's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Alnylam Pharmaceuticals's SG&A?: Alnylam Pharmaceuticals (ALNY) reported SG&A of $347.92M in Q2 2026.
How has Alnylam Pharmaceuticals's SG&A changed year-over-year?: Alnylam Pharmaceuticals's SG&A increased by 7.6% year-over-year, from $323.31M to $347.92M.
What is the long-term trend for Alnylam Pharmaceuticals's SG&A?: Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's SG&A has grown at a 18.2% compound annual growth rate (CAGR), from $620.64M to $1.21B.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.